Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Public ClinicalTrials.gov record NCT05005975. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the long-term safety and tolerability of oral dersimelagon.
Study identification
- NCT ID
- NCT05005975
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 286 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 12 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 10, 2021 (Actual)
- Primary completion
- Dec 2027 (Estimated)
- Completion
- Dec 2027 (Estimated)
- Last update posted
- Sep 9, 2026
2021 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Marvel Clinical Research, LLC | Huntington Beach | California | 92647 | — |
| University of California at San Francisco - CSF Porphyria Center | San Francisco | California | 94143 | — |
| University Of Miami School Of Medicine, Center For Liver Diseases | Miami | Florida | 33136 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| MetroBoston Clinical Partners, LLC | Brighton | Massachusetts | 02135-3211 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Kansas City Research Institute | Kansas City | Missouri | 64131 | — |
| Icahn School of Medicine at Mount Sinai (ISSMS)-The Mount Sinai Hospital (MSH) | New York | New York | 10029 | — |
| Wake Forest University Baptist Health | Winston-Salem | North Carolina | 27157 | — |
| Remington-Davis Clinical Research | Columbus | Ohio | 43215 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| The University of Texas Medical Branch (UTMB) | Galveston | Texas | 77555 | — |
| University of Washington-Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05005975, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05005975 live on ClinicalTrials.gov.